Published in Antimicrob Agents Chemother on August 01, 1983
In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother (1984) 3.66
Evaluation of teicoplanin and vancomycin disk susceptibility tests. J Clin Microbiol (1986) 2.61
Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother (1986) 2.12
Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria. J Clin Microbiol (1987) 1.22
Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother (1989) 1.19
Biochemical and cultural characteristics of "JK" coryneforms. J Clin Pathol (1986) 1.06
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers. Antimicrob Agents Chemother (1992) 0.91
Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob Agents Chemother (1988) 0.85
Determination of teicoplanin concentrations in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother (1987) 0.84
Comparison of the agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of teicoplanin MICs. J Clin Microbiol (1989) 0.79
Concentrations of teicoplanin in serum and atrial appendages of patients undergoing cardiac surgery. Antimicrob Agents Chemother (1990) 0.77
Production of extracellular slime by coryneforms colonizing hydrocephalus shunts. J Clin Microbiol (1994) 0.77
A clinical view of vancomycin in 1990. Tex Heart Inst J (1990) 0.75
Synergistic activity between vancomycin or teicoplanin and gentamicin or tobramycin against pathogenic diphtheroids. Antimicrob Agents Chemother (1988) 0.75
Sepsis with a new species of Corynebacterium. Ann Intern Med (1976) 3.23
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Human cryptosporidiosis: spectrum of disease. Report of six cases and review of the literature. Arch Intern Med (1983) 2.10
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86
The relationship between the thrombotic and infectious complications of central venous catheters. JAMA (1994) 1.85
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
In vitro studies of cefamandole. Antimicrob Agents Chemother (1976) 1.81
Detection of Serratia outbreaks in hospital. Lancet (1976) 1.81
Comparative in vitro activity of cephalosporins. J Antibiot (Tokyo) (1976) 1.79
Valuable of terminal subcultures from negative BACTEC blood culture bottles. J Clin Microbiol (1981) 1.79
Infectious complications of indwelling vascular catheters. Clin Infect Dis (1992) 1.77
Serratia sp. infections in cancer patients. Cancer (1970) 1.73
Comparative in vitro study of temocillin (BRL 17421), a new penicillin. Antimicrob Agents Chemother (1982) 1.73
Clostridial bacteremia in cancer patients. A 12-year experience. Cancer (1991) 1.72
Is a picture worth a thousand medical words? A randomized trial of reporting formats for medical research data. Methods Inf Med (1991) 1.70
Epidemiological studies of Pseudomonas species in patients with leukemia. Am J Med Sci (1970) 1.70
The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol (1968) 1.69
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Bacterial adherence to pharyngeal cells during viral infection. J Infect Dis (1980) 1.68
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med (1989) 1.64
Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med (2000) 1.62
Clinical pharmacology of sisomicin. Antimicrob Agents Chemother (1975) 1.61
Routine use of BACTEC 16B bottles to remove antibacterial and antitumor agents from blood cultures of cancer patients. J Clin Microbiol (1983) 1.59
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother (1984) 1.58
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother (1995) 1.57
The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) (1988) 1.56
Infection in cancer patients. A continuing association. Am J Med (1986) 1.55
Fungal infection and fever of unknown origin in neutropenic patients. Am J Med (1986) 1.54
Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis (1992) 1.54
Mycobacteriosis in patients with malignant disease. Arch Intern Med (1976) 1.54
Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer (1978) 1.53
In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother (1990) 1.52
Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis (1983) 1.52
Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol (1990) 1.51